Quarterly Performance of GlaxoSmithKline’s Global Pharmaceuticals
GlaxoSmithKline’s (GSK) Global Pharmaceuticals business is part of its Pharmaceuticals segment and includes products from immuno-inflammation products, respiratory products, and established products. The Global Pharmaceuticals business reported revenues of 3.2 billion pounds in 2Q17.
Interested in GSK? Don't miss the next report.
Receive e-mail alerts for new research on GSK
The above chart shows revenues for some of the key products in Global Pharmaceuticals. Below are details on the performances of each of these franchises.
Performance of Global Pharmaceuticals
Let’s look at the performances of each franchise in GlaxoSmithKline’s Global Pharmaceuticals business.
The immuno-inflammation franchise, which includes Benlysta, reported a rise of 9.0% in revenues at constant exchange rates to 93.0 million pounds in 2Q17 compared to 2Q16.
The respiratory franchise reported a 4.0% rise in revenues at constant exchange rates to 1.8 billion pounds in 2Q17 compared to 2Q16. Revenue growth was driven by increased sales of Incruse Ellipta, Anoro Ellipta, Arnuity Ellipta, Nucala, and Relvar/Breo Ellipta, partially offset by weak sales of Avamys/Veramyst, Flixotide/Flovent, and Seretide/Advair due to generic competition.
The established pharmaceuticals franchise reported a 7.0% fall in revenues to 1.5 billion pounds in 2Q17 compared to 2Q16. Revenues fell due to lower sales of Avodart following the loss of exclusivity, the impact of the recent divestment of the Romanian distribution business in 4Q16, and the divestment of the thrombosis and anesthesia business to Aspen Technology (AZPN) in 1Q17.
The established pharmaceuticals franchise also includes dermatology products and Augmentin. Dermatology products reported a 17.0% rise in revenues at constant exchange rates in 2Q17, while Augmentin reported a 1.0% fall in revenues at constant exchange rates in 2Q17.